Fractional co2 Laser Followed by Either Vitamin c or Tranexamic Acid in Treatment of Melasma.

Launched by KHADIJA QENAWI · Jun 11, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and safety of a treatment for melasma, which is a common skin condition that causes dark patches on the face. Specifically, the trial will compare the results of using a fractional CO2 laser combined with either vitamin C or tranexamic acid, which are both used to help lighten skin discoloration. The researchers will also look at how well a special tool called a dermoscope helps measure the response to the treatments compared to regular clinical assessments.

To participate in this study, you need to be at least 19 years old and have any type of melasma. However, certain people cannot join, including those who are pregnant or breastfeeding, or those who have taken specific medications that could affect skin color in the past year. Participants can expect to receive one of the treatment combinations and will be monitored for their response. This trial is not yet recruiting, so there will be more information available soon for those interested in taking part.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. All types of melasma (epidermal, dermal, and mixed) will be included .
• • 2. Patients older than 19 years of age.
• Exclusion Criteria:
• • 1. Pregnancy, breastfeeding.
• • 2. Patients taking drugs that induce facial pigmentation e.g, oral contraceptive pills, or hormonal replacement therapy at the time of the study or during the past 12 months.
• • 3. Patients using of any topical bleaching within 1 month before recruitment.
• • 4. Employment of chemical peels or laser therapy during the past 6 months.
• • 5. Concomitant use of anticoagulants, bleeding disorders.